Conclusion of a non-exclusive discount contract according to Section 130a (8) SGB V for drugs with the active substance etanercept (ATC code: L04AB01) within the period from March 1, 2022 to February 29, 2024, with the possibility of concluding the contract at any time during the term (“open-house model”).

The contractual partners can be viewed at: https://www.aok-gesundheitpartner.de/nds/arzneimittel/rabatt/index_03504.html?bl=nds

The AOK Lower Saxony. Until exclusive contracts come into force after a public tender in accordance with the regulations of the 4th part of the GWB, the health fund intends, non-exclusive drug discount contracts for the active substance etanercept (ATC code: L04AB01) with as many market participants as possible (pharmaceutical entrepreneurs or communities) pharmaceutical entrepreneur) in the so-called “open-house model”.

AOK Niedersachsen will not make a selection decision and will submit an identical contract offer to every interested pharmaceutical company. In the open-house model, uniform conditions apply to all participants. Contract contents, conditions and access procedures are uniform — individual negotiations are generally not conducted. The contract terms are a maximum of twenty-four months, the earliest start of the contract is 01.03.2022. All contracts end on 29.02.2024 at the latest, regardless of the date the respective contract was concluded. You can join or conclude a contract within the twenty-four month period on the first of each month. There is a right of termination six weeks to the end of the month. The AOK — The health insurance fund for Lower Saxony reserves the right to replace non-exclusive open-house discount contracts with exclusive discount contracts during the contract period. With the entry into force of advertised exclusive discount contracts, the open-house contracts are terminated in accordance with the contractual regulation, i.e. the open-house contracts end automatically. According to the experience of AOK Niedersachsen, exclusive discount contracts usually come into force six to eight months after the publication of the corresponding tender notice in the supplement to the Official Journal of the European Union. Future contract partners in the open-house model are asked to inform themselves regularly about these tender notices in the supplement to the Official Journal of the European Union.

Interested pharmaceutical companies can request the contractual documents and the contractual terms and conditions at the contact address given under I.1).

Contracts for the active substance etanercept (ATC code: L04AB01) are concluded for the first time with effect from 01.03.2022. Interested parties who wish to become contract partners by this date must submit the contract documents to be submitted to the address specified in the contract documents by 31.01.2022. It depends on access at AOK Niedersachsen. Later contracts can be concluded during the twenty-four-month maximum period on the first of each month. In terms of organization, a lead time of usually 35 calendar days is required by AOK in order to be able to guarantee the necessary work, such as contract notification in the Lauer Tax®. The exact deadlines for receipt will be announced with the contract documents. This publication is not the award of a public contract within the meaning of the Directive (2014/24/EU) or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, they are published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name “open procedure”, are solely due to the use of this announcement form and the publication platform. This does not entail any further meaning, in particular a submission to subprocurement law provisions, unless they are obligatory for legal reasons.